Hostname: page-component-78c5997874-m6dg7 Total loading time: 0 Render date: 2024-11-18T21:28:48.024Z Has data issue: false hasContentIssue false
  • English
  • Français

Lack of congruence between patients' and health professionals' perspectives of adherence to imatinib therapy in treatment of chronic myeloid leukemia: A qualitative study

Published online by Cambridge University Press:  13 February 2014

Simon Wu ,
Desmond Chee ,
Anna Ugalde ,
Phyllis Butow ,
John Seymour  and
Penelope Schofield
Simon Wu
Affiliation:
Department of Cancer Experiences Research, Peter MacCallum Cancer Center, East Melbourne, Victoria, Australia Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, Victoria, Australia
Desmond Chee
Affiliation:
Department of Cancer Experiences Research, Peter MacCallum Cancer Center, East Melbourne, Victoria, Australia Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, Victoria, Australia
Anna Ugalde
Affiliation:
Department of Cancer Experiences Research, Peter MacCallum Cancer Center, East Melbourne, Victoria, Australia Center for Palliative Care, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia
Phyllis Butow
Affiliation:
Department of Psychology, The University of Sydney, Sydney, New South Wales, Australia
John Seymour
Affiliation:
Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, Victoria, Australia Department of Hematology, Peter MacCallum Cancer Center, East Melbourne, Victoria, Australia
Penelope Schofield*
Affiliation:
Department of Cancer Experiences Research, Peter MacCallum Cancer Center, East Melbourne, Victoria, Australia Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, Victoria, Australia Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia
*
Address correspondence and reprint requests to: Penelope Schofield, Peter MacCallum Cancer Center, Locked Bag 1, A'Beckett Street, Victoria, 8006, Australia. E-mail: penelope.schofield@petermac.org.
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

Consistent use of imatinib is critical for treatment success in chronic myeloid leukemia, yet perfect adherence to the prescribed clinical regimen is reported to be as low as 14%. This study aimed to understand patients' experiences of chronic myeloid leukemia with a qualitative approach, including identified facilitators and barriers to adherence, drawing on patients' and health professionals' perspectives, recording comments made by patients and health professionals involved with the same treatment team.

Method:

We recruited patients with chronic myeloid leukemia prescribed imatinib therapy and health professionals involved in their treatment from a specialized cancer center. Semi-structured qualitative interviews were recorded, transcribed, and manually analyzed using interpretive phenomenological analysis. Recruitment ceased upon saturation, with 16 patients and 10 health professionals (hematologists n = 4, nurses n = 3, pharmacists n = 3).

Results:

Twelve patients reported at least one instance of nonadherence. Reasons for unintentional nonadherence included forgetfulness related to variations of routine and doctor–patient communication issues. Reasons for intentional nonadherence included desires to reduce dose-dependent side effects and insufficient support. Patients who reported higher nonadherence rates felt complacent following periods of sustained disease control or had received conflicting advice regarding nonadherence. Health professionals had difficulty in accurately evaluating medication adherence due to a lack of reliable measures, utilizing patient self-report and manifestations of suboptimal disease control to guide assessments.

Significance of Results:

Adherence issues persist throughout the course of treatment. While high patient-reported nonadherence rates were recorded, health professionals were often unaware of the complex causes, compounded by an inadequacy of adherence assessment tools. Some patients reported nonadherence events because of insufficient education or lack of access to prompt medical guidance. These issues should be addressed to improve clinical practice.

Keywords

CancerAdherenceChronic myeloid leukemiaQualitativeImatinib
Type
Original Articles
Information
Palliative & Supportive Care , Volume 13 , Issue 2 , April 2015 , pp. 255 - 263
Copyright
Copyright © Cambridge University Press 2014 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

Abraham, I. & MacDonald, K. (2012). Why are patients with chronic myeloid leukaemia (non-)adherent? British Journal of Cancer, 107(6), 901–903.CrossRefGoogle ScholarPubMed
Baccarani, M., Cortes, J., Pane, F., et al. (2009). Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet. Journal of Clinical Oncology, 27(35), 6041–6051.Google Scholar
Broom, A. & Adams, J. (2009). Oncology clinicians' accounts of discussing complementary and alternative medicine with their patients. Health (London), 13(3), 317–336.Google Scholar
Bryman, A. & Burgess, R.G. (1994). Analyzing qualitative data. London: Routledge.Google Scholar
Cortes, J.E., Egorin, M.J., Guilhot, F., et al. (2009). Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia. Leukemia, 23(9), 1537–1544.Google Scholar
Druker, B.J., Guilhot, F., O'Brien, S.G., et al. (2006). Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. The New England Journal of Medicine, 355(23), 2408–2417.Google Scholar
Efficace, F., Baccarani, M., Rosti, G., et al. (2012). Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: An observational patient-centered outcome study. British Journal of Cancer, 107(6), 904–909.CrossRefGoogle ScholarPubMed
Efficace, F., Rosti, G., Cottone, F., et al. (2013). Profiling chronic myeloid leukemia patients reporting intentional and unintentional non-adherence to lifelong therapy with tyrosine kinase inhibitors. Leukemia Research [Epub ahead of print]. http://dx.doi.org/10.1016/j.leukres.2013.07.003.CrossRefGoogle Scholar
Eliasson, L., Clifford, S., Barber, N., et al. (2011). Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leukemia Research, 35(5), 626–630.CrossRefGoogle ScholarPubMed
Fisher, J.D. & Fisher, W.A. (1992). Changing AIDS-risk behavior. Psychological Bulletin, 111(3), 455–474.CrossRefGoogle ScholarPubMed
Grossman, S. (2011). Management of type 2 diabetes mellitus in the elderly: Role of the pharmacist in a multidisciplinary health care team. Journal of Multidisciplinary Healthcare, 4, 149–154.CrossRefGoogle Scholar
Guilhot, F., Coombs, J., Zernovak, O., et al. (2010). A global retrospective and physician-based analysis of adherence to tyrosine kinase inhibitor (TKI) therapies for chronic myeloid leukemia (CML). ASH Annual Meeting Abstracts, 116(21), 1514.Google Scholar
Hartigan, K. (2003). Patient education: The cornerstone of successful oral chemotherapy treatment. Clinical Journal of Oncology Nursing, 7(6 Suppl.), 21–24.CrossRefGoogle ScholarPubMed
Haynes, R.B., Ackloo, E., Sahota, N., et al. (2008). Interventions for enhancing medication adherence. Cochrane Database of Systematic Reviews, Apr. 16(2), CD000011.Google Scholar
Hehlmann, R., Hochhaus, A. & Baccarani, M. (2007). Chronic myeloid leukaemia. The Lancet, 370(9584), 342–350.Google Scholar
Horne, R. (2006). Compliance, adherence, and concordance: Implications for asthma treatment. Chest, 130(1 Suppl.), 65S–S72.CrossRefGoogle ScholarPubMed
Ibrahim, A.R., Eliasson, L., Apperley, J.F., et al. (2011). Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood, 117(14), 3733–3736.Google Scholar
Jabbour, E., Cortes, J.E., Ghanem, H., et al. (2008). Targeted therapy in chronic myeloid leukemia. Expert Review of Anticancer Therapy, 8(1), 99–110.Google Scholar
Jabbour, E., Saglio, G., Radich, J., et al. (2012). Adherence to BCR–ABL inhibitors: Issues for CML therapy. Clinical Lymphoma, Myeloma & Leukemia, 12(4), 223–229.Google Scholar
Kantarjian, H.M., Talpaz, M., O'Brien, S., et al. (2006). Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood, 108(6), 1835–1840.CrossRefGoogle ScholarPubMed
Kearney, N., McCann, L., Norrie, J., et al. (2009). Evaluation of a mobile phone-based, advanced symptom management system (ASyMS) in the management of chemotherapy-related toxicity. Supportive Care in Cancer, 17(4), 437–444.Google Scholar
Marin, D., Bazeos, A., Mahon, F.X., et al. (2010). Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. Journal of Clinical Oncology, 28(14), 2381–2388.Google Scholar
Monti, D.A. & Yang, J. (2005). Complementary medicine in chronic cancer care. Seminars in Oncology, 32(2), 225–231.CrossRefGoogle ScholarPubMed
Murchie, P., Delaney, E.K., Campbell, N.C., et al. (2009). GP-led melanoma follow-up: The practical experience of GPs. Family Practice, 26(4), 317–324.Google Scholar
Noens, L., van Lierde, M.A., De Bock, R., et al. (2009). Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: The ADAGIO study. Blood, 113(22), 5401–5411.Google Scholar
Osterberg, L. & Blaschke, T. (2005). Adherence to medication. The New England Journal of Medicine, 353(5), 487–497.Google Scholar
Peng, B., Hayes, M., Resta, D., et al. (2004). Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. Journal of Clinical Oncology, 22(5), 935–942.Google Scholar
Regnier, Denois V., Poirson, J., Nourissat, A., et al. (2011). Adherence with oral chemotherapy: Results from a qualitative study of the behaviour and representations of patients and oncologists. European Journal of Cancer Care, 20, 520–527.Google Scholar
Richardson, M.A., Masse, L.C., Nanny, K., et al. (2004). Discrepant views of oncologists and cancer patients on complementary/alternative medicine. Supportive Care in Cancer, 12(11), 797–804.CrossRefGoogle ScholarPubMed
Roter, D.L., Hall, J.A., Merisca, R., et al. (1998). Effectiveness of interventions to improve patient compliance: A meta-analysis. Medical Care, 36(8), 1138–1161.Google Scholar
Ruddy, K., Mayer, E. & Partridge, A. (2009). Patient adherence and persistence with oral anticancer treatment. CA: A Cancer Journal for Clinicians, 59(1), 56–66.Google Scholar
Sabate, E. (2003). Adherence to long-term therapies: Evidence for action. Geneva: World Health Organization.Google Scholar
Schofield, P.E., Juraskova, I. & Butow, P.N. (2003). How oncologists discuss complementary therapy use with their patients: An audio-tape audit. Supportive Care in Cancer, 11(6), 348–355.Google Scholar
Schofield, P., Diggens, J., Charleson, C., et al. (2010). Effectively discussing complementary and alternative medicine in a conventional oncology setting: Communication recommendations for clinicians. Patient Education and Counseling, 79(2), 143–151.Google Scholar
Smith, J.A., Flowers, P. & Larkin, M. (2009). Interpretive phenomenological analysis: Theory method and research. London: Sage.Google Scholar
Stanton, A.L., Danoff-Burg, S., Cameron, C.L., et al. (1999). Social comparison and adjustment to breast cancer: An experimental examination of upward affiliation and downward evaluation. Health Psychology, 18(2), 151–158.CrossRefGoogle ScholarPubMed
Stone, R.M. (2004). Optimizing treatment of chronic myeloid leukemia: A rational approach. The Oncologist, 9(3), 259–270.Google Scholar
Taylor, S.E. & Lobel, M. (1989). Social comparison activity under threat: Downward evaluation and upward contacts. Psychological Review, 96(4), 569–575.Google Scholar
Williams, A.B. (2001). Adherence to HIV regimens: 10 vital lessons. The American Journal of Nursing, 101(6), 37–43.CrossRefGoogle ScholarPubMed
Winkeljohn, D. (2010). Adherence to oral cancer therapies: Nursing interventions. Clinical Journal of Oncology Nursing, 14(4), 461–466.Google Scholar
Yoshida, C., Komeno, T., Hori, M., et al. (2011). Adherence to the standard dose of imatinib, rather than dose adjustment based on its plasma concentration, is critical to achieve a deep molecular response in patients with chronic myeloid leukemia. International Journal of Hematology, 93(5), 618–623.CrossRefGoogle Scholar